Suscribirse

Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry - 16/04/21

Doi : 10.1016/j.biopha.2021.111469 
Giuseppe De Luca a, , Miha Cercek b, Lisette Okkels Jensen c, Oliver Bushljetikj d, Lucian Calmac e, Tom Johnson f, Montserrat Gracida Blancas g, Vladimir Ganyukov h, Wojtek Wojakowski i, Clemens von Birgelen j, Alexander IJsselmuiden k, Bernardo Tuccillo l, Francesco Versaci m, Jurrien Ten Berg n, Mika Laine o, Tim Berkout p, Gianni Casella q, Petr Kala r, Bernabé López Ledesma s, Victor Becerra t, Roberto Padalino u, Andrea Santucci v, Xavier Carrillo w, Alessandra Scoccia x, Giovanni Amoroso bl, Arpad Lux y, Tomas Kovarnik z, Periklis Davlouros aa, Gabriele Gabrielli ab, Xacobe Flores Rios ac, Nikola Bakraceski ad, Sébastien Levesque ae, Vincenzo Guiducci af, Michał Kidawa ag, Lucia Marinucci ah, Filippo Zilio ai, Gennaro Galasso aj, Enrico Fabris ak, Maurizio Menichelli al, Stephane Manzo am, Gianluca Caiazzo an, Jose Moreu ao, Juan Sanchis Forés ap, Luca Donazzan aq, Luigi Vignali ar, Rui Teles as, Pierfrancesco Agostoni at, Francisco Bosa Ojeda au, Heidi Lehtola av, Santiago Camacho-Freiere aw, Adriaan Kraaijeveld ax, Ylitalo Antti ay, Gabriella Visconti az, Iñigo Lozano Martínez-Luengas ba, Bruno Scheller bb, Dimitrios Alexopulos bc, Raul Moreno bd, Elvin Kedhi be, Giuseppe Uccello bf, Benjamin Faurie bg, Alejandro Gutierrez Barrios bh, Fortunato Scotto Di Uccio l, Bor Wilbert n, Giuliana Cortese bi, Maurits T. Dirksen p, Guido Parodi bj, Monica Verdoia bk
a Division of Cardiology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Università del Piemonte Orientale, Italy 
b Centre for Intensive Internal Medicine, University Medical Centre, Ljubljana, Slovenia 
c Division of Cardiology, Odense Universitets Hospital, Odense, Denmark 
d University Clinic for Cardiology, Medical Faculty, Ss' Cyril and Methodius University, Skopje, North Macedonia 
e Clinic Emergency Hospital of Bucharest, Romania 
f Division of Cardiology, Bristol Heart Institute, University Hospitals Bristol NHSFT & University of Bristol, Bristol 
g Interventional Cardiology Unit, Heart Disease Institute, Hospital Universitari de Bellvitge, Spain 
h Division of Cardiology, State Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Kemerovo, Russia 
i Division of Cardiology, Medical University of Silezia, Katowice, Poland 
j Department of Cardiology, Medisch Spectrum Twente, Thoraxcentrum Twente, Enschede, The Netherlands 
k Division of Cardiology, Amphia Hospital, Breda, The Netherlands 
l Division of Cardiology, Ospedale del Mare, Napoli, Italy 
m Division of Cardiology, Ospedale Santa Maria Goretti Latina, Italy 
n Division of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands 
o Division of Cardiology, Helsinki University Central Hospital, Finland 
p Division of Cardiology, Northwest Clinics Alkmaar, The Netherlands 
q Division of Cardiology, Ospedale Maggiore Bologna, Italy 
r University Hospital Brno, Medical Faculty of Masaryk University Brno, Czech Republic 
s H. Universitario y Politécnico La Fe, Valencia, Spain 
t Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain 
u Division of Cardiology, Clinica Villa dei Fiori, Acerra, Italy 
v Ospedale Santa Maria della Misericordia, Perugia, Italy 
w Hospital Germans Triasi Pujol, Badalona, Spain 
x Division of Cardiology, Ospedale “Sant’Anna”, Ferrara, Italy 
y Maastricht University Medical Center, The Netherlands 
z University Hospital Prague, Czech Republic 
aa Invasive Cardiology and Congenital Heart Disease, Patras University Hospital, Patras, Greece 
ab Interventional Cardiology Unit, Azienda Ospedaliero Universitaria “Ospedali Riuniti”, Ancona, Italy 
ac Complexo Hospetaliero Universitario La Coruna, La Coruna, Spain 
ad Center for Cardiovascular Diseases, Ohrid, North Macedonia 
ae Center Hospitalier Universitaire de Poitiers, Poitiers, University Hospital, Poitiers, France 
af AUSL-IRCCS Reggio Emilia, Italy 
ag Central Hospital of Medical University of Lodz, Poland 
ah Division of Cardiology, Azienda Ospedaliera “Ospedali Riuniti Marche Nord”, Pesaro, Italy 
ai Ospedale Santa Chiara di Trento, Italy 
aj Division of Cardiology, Ospedale San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy 
ak Azienda Ospedaliero – Universitaria Ospedali Riuniti Trieste, Italy 
al Division of Cardiology, Ospedale “F. Spaziani“, Frosinone, Italy 
am Division of Cardiology, CHU Lariboisière, AP-HP, Paris VII University, INSERM UMRS 942, France 
an Division of Cardiology, Ospedale “G Moscati”, Aversa, Italy 
ao Division of Cardiology, Complejo Hospitalario de Toledo, Toledo, Spain 
ap Division of Cardiology, Hospital Clinico Universitario de Valencia, Spain 
aq Division of Cardiology, Ospedale ”S. Maurizio” Bolzano Ospedale ”S. Maurizio” Bolzano (OR), Italy 
ar Interventional Cardiology Unit, Azienda Ospedaliera Sanitaria, Parma, Italy 
as Division of Cardiology, Hospital de Santa Cruz, CHLO, Carnaxide, Portugal 
at Division of Cardiology, Ziekenhuis Netwerk Antwerpen (ZNA) Middelheim, Antwerp, Belgium 
au Division of Cardiology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain 
av Division of Cardiology, Oulu University Hospital, Finland 
aw Division of Cardiology, Juan Ramon Jimenez Hospital, Huelva, Spain 
ax Division of Cardiology, UMC Utrecht, The Netherlands 
ay Division of Cardiology, Heart Centre Turku, Finland 
az Division of Cardiology, Ospedale Santa Maria delle Grazie, Pozzuoli, Italy 
ba Division of Cardiology, Hospital Cabueñes, Gijon, Spain 
bb Division of Cardiology, Clinical and Experimental Interventional Cardiology, University of Saarland, Germany 
bc Division of Cardiology, Attikon University Hospital, Athens, Greece 
bd Division of Cardiology, Hospital la Paz, Madrid, Spain 
be Division of Cardiology, St-Jan Hospital, Brugge, Belgium 
bf Division of Cardiology, Ospedale "A. Manzoni" Lecco, Italy 
bg Division of Cardiology, Groupe Hospitalier Mutualiste de Grenoble, France 
bh Division of Cardiology, Hospital Puerta del Mar, Cadiz, Spain 
bi Department of Statistical Sciences, University of Padova, Italy 
bj Azienda Ospedaliero-Universitaria Sassari, Italy 
bk Division of Cardiology, Ospedale degli Infermi, ASL Biella, Italy 
bl Onze Lieve Gasthuis; Amsterdam, The Netherlands 

Correspondence to: Prof Giuseppe De Luca, Eastern Piedmont University, Novara, Italy.Prof Giuseppe De Luca, Eastern Piedmont UniversityNovaraItaly

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Concerns have been raised on a potential interaction between renin-angiotensin system inhibitors (RASI) and the susceptibility to coronavirus disease 2019 (COVID-19). No data have been so far reported on the prognostic impact of RASI in patients suffering from ST-elevation myocardial infarction (STEMI) during COVID-19 pandemic, which was the aim of the present study.

Methods

STEMI patients treated with primary percutaneous coronary intervention (PPCI) and enrolled in the ISACS-STEMI COVID-19 registry were included in the present sub-analysis and divided according to RASI therapy at admission.

Results

Our population is represented by 6095 patients, of whom 3654 admitted in 2019 and 2441 in 2020. No difference in the prevalence of SARSCoV2 infection was observed according to RASI therapy at admission (2.5% vs 2.1%, p = 0.5), which was associated with a significantly lower mortality (adjusted OR [95% CI]=0.68 [0.51–0.90], P = 0.006), confirmed in the analysis restricted to 2020 (adjusted OR [95% CI]=0.5[0.33–0.74], P = 0.001). Among the 5388 patients in whom data on in-hospital medication were available, in-hospital RASI therapy was associated with a significantly lower mortality (2.1% vs 16.7%, OR [95% CI]=0.11 [0.084–0.14], p < 0.0001), confirmed after adjustment in both periods. Among the 62 SARSCoV-2 positive patients, RASI therapy, both at admission or in-hospital, showed no prognostic effect.

Conclusions

This is the first study to investigate the impact of RASI therapy on the prognosis and SARSCoV2 infection of STEMI patients undergoing PPCI during the COVID-19 pandemic. Both pre-admission and in-hospital RASI were associated with lower mortality. Among SARSCoV2-positive patients, both chronic and in-hospital RASI therapy showed no impact on survival.

El texto completo de este artículo está disponible en PDF.

Keywords : Renin-Angiotensin System inhibitors, ST-segment elevation myocardial infarction, Mortality, COVID-19, Percutaneous coronary intervention


Esquema


© 2021  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 138

Artículo 111469- juin 2021 Regresar al número
Artículo precedente Artículo precedente
  • Parecoxib improves atherosclerotic plaque stability by suppressing inflammation and inhibiting matrix metalloproteinases production
  • Chao Gong, Yu Qi, Yang Xu, Xiruo Tang, Feng Liang, Lianhua Chen
| Artículo siguiente Artículo siguiente
  • Rhizoma drynariae total flavonoids inhibit the inflammatory response and matrix degeneration via MAPK pathway in a rat degenerative cervical intervertebral disc model
  • Kai Zhao, Min Chen, Ting Liu, Panpan Zhang, Sheng Wang, Xiangguo Liu, Qunan Wang, Jie Sheng

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.